BRCA1 and BRCA2 mutation carriers can reduce their risk of ovarian, Fallopian and peritoneal cancer by 80% by removing both ovaries and tubes. This has not been the understanding to date, but recent data presented at ASCO confirms this staggering risk reduction of the related cancers. Furthermore, there is a 77% reduction in risk of death from all causes.
The following is a press release from Caris Life Sciences about a breakthrough presentation of data at the recent American Society for Clinical Oncology (ASCO) meeting. In this study, the median overall survival was eight years longer in ovarian and fallopian tube cancer patients treated using Caris Molecular Intelligence profiling vs. those who did not. In a subset of patients who recurred, using this technology patients lived two and a half years longer. The details are summarized in the release as follows: